Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies.

ABSTRACT: Cancer cachexia syndrome (CCS) is a multifactorial metabolic syndrome affecting a significant proportion of patients. CCS is characterized by progressive weight loss, alterations of body composition and a systemic inflammatory status, which exerts a major impact on the host's innate and adaptive immunity. Over the last few years, the development of immune checkpoint inhibitors (ICIs) transformed the treatment landscape for a wide spectrum of malignancies, creating an unprecedented opportunity for long term remissions in a significant subset of patients. Early clinical data indicate that CCS adversely impairs treatment outcomes of patients receiving ICIs. We herein reviewed existing evidence on the potential links between the mechanisms that promote the catabolic state in CCS and those that

SUBMITTER: Rounis K 

PROVIDER: S-EPMC9225288 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature